TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB33288

Peptide_Name

NN-32

Activity

Anticancer Toxicity

Activity_category_statistics

Cancer-related peptides Toxicity and safety peptides

Database_Source

CancerPPD 2.0 Peptipedia ToxinPred 3.0

Sequence_Type

standard

Has_Modification No

Description A 10-aa standard natural multi-activity (Anticancer and Toxicity) peptide sequence curated from CancerPPD 2.0, Peptipedia, and ToxinPred 3.0, with an available 3D structural model.

Sequence

LKCNKLVPLF

FASTA

>TPDB33288|Anticancer;Toxicity|length=10
LKCNKLVPLF

Formula C56H95N13O12S1

Absent Amino Acids ARDEQGHIMSTWY

Common Amino Acids L

Mass 1174.51

PI 9.90

Basic Residues 2

Acidic Residues 0

Hydrophobic Residues 5

Net Charge +2

Boman Index -0.13

Hydrophobicity 0.800

Aliphatic Index 146.00

Half Life

Mammalian: 5.5 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 0

Absorbance 280nm 0.00

Polar Residues 2

number

0

A

0

R

1

N

0

D

1

C

0

E

0

Q

0

G

0

H

0

I

3

L

2

K

0

M

1

F

1

P

0

S

0

T

0

W

0

Y

1

V

Amino Acid Distribution

A: 0 R: 0 N: 1 D: 0 C: 1 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 3 K: 2 M: 0 F: 1 P: 1 S: 0 T: 0 W: 0 Y: 0 V: 1

Length

10

Formula

C56H95N13O12S1

Mass

1174.51

PI

9.90

Net Charge

+2

Boman Index

-0.13

Hydrophobicity

0.800

C_terminal_Modification

Free

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Anticancer

Origin

Indian spectacled cobra venom Naja naja

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 2.5 µg/ml

Detail Source Activity Anticancer

Activity Measurement 2.5 µg/mL

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2017

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 6.7 µg/ml

Detail Source Activity Anticancer

Activity Measurement 6.7 µg/mL

Target

Cancer Type Breast Cancer

Cell Line MDA-MB-231

Tissue Affected Breast

Assay & Model

Assay MTT assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2017

Evidence 3 Activity

Activity

Activity Raw

Survival(%) = 68% at 10 µg/ml

Detail Source Activity Anticancer

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay Anti-proliferation assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2017

Evidence 4 Activity

Activity

Activity Raw

Survival(%) = 64% at 10 µg/ml

Detail Source Activity Anticancer

Target

Cancer Type Breast Cancer

Cell Line MDA-MB-231

Tissue Affected Breast

Assay & Model

Assay Anti-proliferation assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2017

Evidence 5 Activity

Activity

Activity Raw

74% LDH Release at 2 µg/ml

Detail Source Activity Anticancer

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay LDH leakage assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2017

Evidence 6 Activity

Activity

Activity Raw

66% LDH Release at 2 µg/ml

Detail Source Activity Anticancer

Target

Cancer Type Breast Cancer

Cell Line MDA-MB-231

Tissue Affected Breast

Assay & Model

Assay LDH leakage assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2017